Disease · MONDO_0015265

bronchiolitis obliterans syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bronchiolitis obliterans syndrome. Diseases, record MONDO_0015265. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015265

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bronchiolitis obliterans syndrome; Open Targets
Open Targets ID: MONDO_0015265; Open Targets
Other names: BOOP, Bronchiolitis Obliterans, Bronchiolitis exudativa, Bronchiolitis fibrosa obliterans (disorder), Obliterative bronchiolitis, constrictive bronchiolitis, organised pneumonia, organized pneumonia; Open Targets
Disease Ontology: DOID:2799; Disease Ontology
Orphanet: ORPHA:1303; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 31 drugs, from ClinicalTrials.gov; Open Targets

Drugs31

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOSPORINE	CHEMBL160	Protein	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
NINTEDANIB	CHEMBL502835	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PIRFENIDONE	CHEMBL1256391	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
MONTELUKAST	CHEMBL787	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2	ClinicalTrials.gov	3	3	1	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	CHEMBL4297879	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BUDESONIDE	CHEMBL1370	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUTICASONE PROPIONATE	CHEMBL1473	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets

1 to 10 of 31

See all 31 drugs

Targets61

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	14	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
CYSLTR1	Cysteinyl leukotriene receptor 1	2	Cysteinyl leukotriene receptor 1 antagonist	Phase 2	https://conductscience.org/library/genes/10800	Drugs and targets
ELANE	Neutrophil elastase	2	Leukocyte elastase inhibitor	Phase 2	https://conductscience.org/library/genes/1991	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	2	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor agonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
ADRM1	26S proteasome	1	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets
FGFR1	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2260	Drugs and targets
FGFR2	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2263	Drugs and targets
FGFR3	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2261	Drugs and targets
FGFR4	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2264	Drugs and targets

1 to 10 of 61

See all 61 targets

Trials35

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03656926	Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)	Phase 3	169	2025-07-24	Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT03657342	Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)	Phase 3	62	2025-10-27	Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT01307462	Targeted Therapy of Bronchiolitis Obliterans Syndrome	Phase 2	36	2017-10-04	Bronchiolitis Obliterans	AZITHROMYCIN, FLUTICASONE PROPIONATE, MONTELUKAST SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00656058	Montelukast to Treat Bronchiolitis Obliterans	Phase 2	25	2016-10-21	Bronchiolitis Obliterans, Chronic Graft Versus Host Disease, Leukotriene, Montelukast, Stem Cell Transplant	MONTELUKAST	Its record names the disease	ClinicalTrials.gov
NCT01287078	Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome	Phase 2	25	2020-09-24	Constrictive Bronchiolitis, Bronchiolitis Obliterans, Graft vs Host Disease, Bronchiolitis, Exudative, Bronchiolitis, Proliferative	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT03978637	Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation	Phase 1/2	23	2025-01-29	Bronchiolitis Obliterans Syndrome	ITACITINIB	Its record names the disease	ClinicalTrials.gov
NCT01650545	Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients	Phase 1/2	21	2017-10-25	Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT01163786	A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD	Phase 2	17	2020-04-10	Bronchiolitis Obliterans	BORTEZOMIB	Its record names the disease	ClinicalTrials.gov
NCT01273207	Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans	Phase 2	7	2020-09-18	Bronchiolitis Obliterans, Constructive Bronchiolitis, Graft Versus Host Disease, Bronchiolitis, Exudative, Bronchiolitis, Proliferative, Graft-Versus-Host Disease	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT04107675	A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)	Phase 2	6	2023-10-03	Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic, Stem Cell Transplant Complications	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 35

See all 35 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
L-CsA Treatment Plus SoC - SAF vs Standard of Care - SAF: deaths from any cause	2 of 84	4 of 85	169	NCT03656926	Trial comparisons
L-CsA Treatment Plus SoC - SAF vs Standard of Care - SAF: serious adverse events	46 of 84	44 of 85	169	NCT03656926	Trial comparisons
L-CsA treatment plus SoC (SAF) vs SoC alone (SAF): deaths from any cause	6 of 32	3 of 30	62	NCT03657342	Trial comparisons
L-CsA treatment plus SoC (SAF) vs SoC alone (SAF): serious adverse events	20 of 32	14 of 30	62	NCT03657342	Trial comparisons
Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: deaths from any cause	0 of 20	0 of 3	23	NCT01287078	Trial comparisons
Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: serious adverse events	5 of 20	0 of 3	23	NCT01287078	Trial comparisons
Liposomal Aerosol Cyclosporine vs Conventional Oral Immune Suppression: Number Of Participants With Chronic Rejection Who Met Primary Combined End-point	2 of 11	5 of 10	21	NCT01650545	Trial comparisons
Liposomal Aerosol Cyclosporine vs Conventional Oral Immune Suppression: Overall Survival at 5 Years Follow-up	5 of 11	0 of 10	21	NCT01650545	Trial comparisons
Liposomal Aerosol Cyclosporine vs Conventional Oral Immune Suppression: deaths from any cause	6 of 11	10 of 10	21	NCT01650545	Trial comparisons
Liposomal Aerosol Cyclosporine vs Conventional Oral Immune Suppression: serious adverse events	8 of 11	8 of 10	21	NCT01650545	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26475726	RESULT	1	PubMed
16407509	RESULT	1	PubMed
41964069	DERIVED	1	PubMed
40554417	DERIVED	1	PubMed
39365992	DERIVED	1	PubMed
38485149	DERIVED	3	PubMed
35641662	DERIVED	1	PubMed
34887325	DERIVED	1	PubMed
34126278	DERIVED	1	PubMed
31668569	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015265

GET https://conductscience.org/api/diseases/v1/MONDO_0015265/drugs?page=2

API reference For AI assistants